nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—PDE4D—prostate cancer	0.678	1	CbGaD
Roflumilast—PDE4D—prostate gland—prostate cancer	0.00269	0.205	CbGeAlD
Roflumilast—PDE4A—prostate gland—prostate cancer	0.00238	0.182	CbGeAlD
Roflumilast—PDE4B—prostate gland—prostate cancer	0.00142	0.108	CbGeAlD
Roflumilast—PDE4D—testis—prostate cancer	0.00119	0.0904	CbGeAlD
Roflumilast—PDE4A—testis—prostate cancer	0.00105	0.08	CbGeAlD
Roflumilast—PDE4B—urethra—prostate cancer	0.00095	0.0725	CbGeAlD
Roflumilast—PDE4D—lymph node—prostate cancer	0.000859	0.0655	CbGeAlD
Roflumilast—PDE4A—lymph node—prostate cancer	0.00076	0.058	CbGeAlD
Roflumilast—PDE4B—bone marrow—prostate cancer	0.000731	0.0558	CbGeAlD
Roflumilast—PDE4B—testis—prostate cancer	0.000625	0.0477	CbGeAlD
Roflumilast—PDE4B—lymph node—prostate cancer	0.000453	0.0346	CbGeAlD
Roflumilast—Headache—Goserelin—prostate cancer	0.000152	0.000706	CcSEcCtD
Roflumilast—Malnutrition—Docetaxel—prostate cancer	0.000152	0.000705	CcSEcCtD
Roflumilast—Rash—Conjugated Estrogens—prostate cancer	0.000152	0.000704	CcSEcCtD
Roflumilast—Dermatitis—Conjugated Estrogens—prostate cancer	0.000151	0.000703	CcSEcCtD
Roflumilast—Headache—Conjugated Estrogens—prostate cancer	0.000151	0.0007	CcSEcCtD
Roflumilast—Gastritis—Epirubicin—prostate cancer	0.00015	0.000699	CcSEcCtD
Roflumilast—Dysgeusia—Docetaxel—prostate cancer	0.000149	0.000691	CcSEcCtD
Roflumilast—Infection—Etoposide—prostate cancer	0.000148	0.000688	CcSEcCtD
Roflumilast—Mental disorder—Capecitabine—prostate cancer	0.000148	0.000687	CcSEcCtD
Roflumilast—Connective tissue disorder—Prednisone—prostate cancer	0.000148	0.000687	CcSEcCtD
Roflumilast—Feeling abnormal—Mitoxantrone—prostate cancer	0.000148	0.000686	CcSEcCtD
Roflumilast—Malnutrition—Capecitabine—prostate cancer	0.000147	0.000683	CcSEcCtD
Roflumilast—Influenza—Epirubicin—prostate cancer	0.000147	0.000683	CcSEcCtD
Roflumilast—Back pain—Docetaxel—prostate cancer	0.000147	0.000682	CcSEcCtD
Roflumilast—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000147	0.000681	CcSEcCtD
Roflumilast—Muscle spasms—Docetaxel—prostate cancer	0.000146	0.000678	CcSEcCtD
Roflumilast—Skin disorder—Etoposide—prostate cancer	0.000145	0.000673	CcSEcCtD
Roflumilast—Nausea—Goserelin—prostate cancer	0.000144	0.00067	CcSEcCtD
Roflumilast—Dysgeusia—Capecitabine—prostate cancer	0.000144	0.000669	CcSEcCtD
Roflumilast—Nausea—Conjugated Estrogens—prostate cancer	0.000143	0.000663	CcSEcCtD
Roflumilast—Urticaria—Mitoxantrone—prostate cancer	0.000142	0.000662	CcSEcCtD
Roflumilast—Back pain—Capecitabine—prostate cancer	0.000142	0.000661	CcSEcCtD
Roflumilast—Hypersensitivity—Estradiol—prostate cancer	0.000142	0.000658	CcSEcCtD
Roflumilast—Abdominal pain—Mitoxantrone—prostate cancer	0.000142	0.000658	CcSEcCtD
Roflumilast—Muscle spasms—Capecitabine—prostate cancer	0.000141	0.000657	CcSEcCtD
Roflumilast—Gastritis—Doxorubicin—prostate cancer	0.000139	0.000647	CcSEcCtD
Roflumilast—Asthenia—Estradiol—prostate cancer	0.000138	0.000641	CcSEcCtD
Roflumilast—Tremor—Capecitabine—prostate cancer	0.000138	0.00064	CcSEcCtD
Roflumilast—Ill-defined disorder—Capecitabine—prostate cancer	0.000136	0.000634	CcSEcCtD
Roflumilast—Influenza—Doxorubicin—prostate cancer	0.000136	0.000632	CcSEcCtD
Roflumilast—Immune system disorder—Prednisone—prostate cancer	0.000136	0.000631	CcSEcCtD
Roflumilast—Palpitations—Docetaxel—prostate cancer	0.000134	0.000623	CcSEcCtD
Roflumilast—Weight decreased—Epirubicin—prostate cancer	0.000133	0.000618	CcSEcCtD
Roflumilast—Malaise—Capecitabine—prostate cancer	0.000133	0.000616	CcSEcCtD
Roflumilast—Vertigo—Capecitabine—prostate cancer	0.000132	0.000614	CcSEcCtD
Roflumilast—Hypersensitivity—Mitoxantrone—prostate cancer	0.000132	0.000614	CcSEcCtD
Roflumilast—Pneumonia—Epirubicin—prostate cancer	0.000132	0.000612	CcSEcCtD
Roflumilast—Mental disorder—Prednisone—prostate cancer	0.000132	0.000612	CcSEcCtD
Roflumilast—Diarrhoea—Estradiol—prostate cancer	0.000132	0.000611	CcSEcCtD
Roflumilast—Infestation NOS—Epirubicin—prostate cancer	0.000131	0.000609	CcSEcCtD
Roflumilast—Infestation—Epirubicin—prostate cancer	0.000131	0.000609	CcSEcCtD
Roflumilast—Malnutrition—Prednisone—prostate cancer	0.000131	0.000608	CcSEcCtD
Roflumilast—Palpitations—Capecitabine—prostate cancer	0.00013	0.000603	CcSEcCtD
Roflumilast—Decreased appetite—Etoposide—prostate cancer	0.00013	0.000602	CcSEcCtD
Roflumilast—Myalgia—Docetaxel—prostate cancer	0.000129	0.0006	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Etoposide—prostate cancer	0.000129	0.000598	CcSEcCtD
Roflumilast—Asthenia—Mitoxantrone—prostate cancer	0.000129	0.000597	CcSEcCtD
Roflumilast—Fatigue—Etoposide—prostate cancer	0.000129	0.000597	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000128	0.000596	CcSEcCtD
Roflumilast—Constipation—Etoposide—prostate cancer	0.000127	0.000592	CcSEcCtD
Roflumilast—Urinary tract infection—Epirubicin—prostate cancer	0.000127	0.000592	CcSEcCtD
Roflumilast—Dizziness—Estradiol—prostate cancer	0.000127	0.000591	CcSEcCtD
Roflumilast—Myalgia—Capecitabine—prostate cancer	0.000125	0.000581	CcSEcCtD
Roflumilast—Anxiety—Capecitabine—prostate cancer	0.000125	0.000579	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000124	0.000577	CcSEcCtD
Roflumilast—Hepatobiliary disease—Epirubicin—prostate cancer	0.000124	0.000576	CcSEcCtD
Roflumilast—Discomfort—Capecitabine—prostate cancer	0.000124	0.000574	CcSEcCtD
Roflumilast—Infection—Docetaxel—prostate cancer	0.000123	0.000572	CcSEcCtD
Roflumilast—Weight decreased—Doxorubicin—prostate cancer	0.000123	0.000572	CcSEcCtD
Roflumilast—Sinusitis—Epirubicin—prostate cancer	0.000123	0.000571	CcSEcCtD
Roflumilast—Feeling abnormal—Etoposide—prostate cancer	0.000123	0.000571	CcSEcCtD
Roflumilast—Diarrhoea—Mitoxantrone—prostate cancer	0.000123	0.00057	CcSEcCtD
Roflumilast—Vomiting—Estradiol—prostate cancer	0.000122	0.000568	CcSEcCtD
Roflumilast—Pneumonia—Doxorubicin—prostate cancer	0.000122	0.000567	CcSEcCtD
Roflumilast—Gastrointestinal pain—Etoposide—prostate cancer	0.000122	0.000566	CcSEcCtD
Roflumilast—Nervous system disorder—Docetaxel—prostate cancer	0.000121	0.000565	CcSEcCtD
Roflumilast—Ill-defined disorder—Prednisone—prostate cancer	0.000121	0.000564	CcSEcCtD
Roflumilast—Rash—Estradiol—prostate cancer	0.000121	0.000564	CcSEcCtD
Roflumilast—Infestation NOS—Doxorubicin—prostate cancer	0.000121	0.000563	CcSEcCtD
Roflumilast—Infestation—Doxorubicin—prostate cancer	0.000121	0.000563	CcSEcCtD
Roflumilast—Dermatitis—Estradiol—prostate cancer	0.000121	0.000563	CcSEcCtD
Roflumilast—Headache—Estradiol—prostate cancer	0.00012	0.00056	CcSEcCtD
Roflumilast—Skin disorder—Docetaxel—prostate cancer	0.00012	0.000559	CcSEcCtD
Roflumilast—Angioedema—Prednisone—prostate cancer	0.00012	0.000556	CcSEcCtD
Roflumilast—Infection—Capecitabine—prostate cancer	0.000119	0.000554	CcSEcCtD
Roflumilast—Urticaria—Etoposide—prostate cancer	0.000118	0.00055	CcSEcCtD
Roflumilast—Malaise—Prednisone—prostate cancer	0.000118	0.000549	CcSEcCtD
Roflumilast—Rhinitis—Epirubicin—prostate cancer	0.000118	0.000548	CcSEcCtD
Roflumilast—Abdominal pain—Etoposide—prostate cancer	0.000118	0.000548	CcSEcCtD
Roflumilast—Urinary tract infection—Doxorubicin—prostate cancer	0.000118	0.000548	CcSEcCtD
Roflumilast—Nervous system disorder—Capecitabine—prostate cancer	0.000118	0.000547	CcSEcCtD
Roflumilast—Vertigo—Prednisone—prostate cancer	0.000118	0.000547	CcSEcCtD
Roflumilast—Skin disorder—Capecitabine—prostate cancer	0.000117	0.000541	CcSEcCtD
Roflumilast—Connective tissue disorder—Epirubicin—prostate cancer	0.000116	0.000537	CcSEcCtD
Roflumilast—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000115	0.000533	CcSEcCtD
Roflumilast—Nausea—Estradiol—prostate cancer	0.000114	0.000531	CcSEcCtD
Roflumilast—Vomiting—Mitoxantrone—prostate cancer	0.000114	0.000529	CcSEcCtD
Roflumilast—Sinusitis—Doxorubicin—prostate cancer	0.000114	0.000528	CcSEcCtD
Roflumilast—Rash—Mitoxantrone—prostate cancer	0.000113	0.000525	CcSEcCtD
Roflumilast—Dermatitis—Mitoxantrone—prostate cancer	0.000113	0.000525	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000113	0.000524	CcSEcCtD
Roflumilast—Headache—Mitoxantrone—prostate cancer	0.000112	0.000522	CcSEcCtD
Roflumilast—Insomnia—Docetaxel—prostate cancer	0.000112	0.000521	CcSEcCtD
Roflumilast—Myalgia—Prednisone—prostate cancer	0.000111	0.000518	CcSEcCtD
Roflumilast—Anxiety—Prednisone—prostate cancer	0.000111	0.000516	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000111	0.000514	CcSEcCtD
Roflumilast—Discomfort—Prednisone—prostate cancer	0.00011	0.000512	CcSEcCtD
Roflumilast—Hypersensitivity—Etoposide—prostate cancer	0.00011	0.00051	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000109	0.000508	CcSEcCtD
Roflumilast—Cardiac disorder—Epirubicin—prostate cancer	0.000109	0.000507	CcSEcCtD
Roflumilast—Rhinitis—Doxorubicin—prostate cancer	0.000109	0.000507	CcSEcCtD
Roflumilast—Dyspepsia—Docetaxel—prostate cancer	0.000109	0.000507	CcSEcCtD
Roflumilast—Insomnia—Capecitabine—prostate cancer	0.000108	0.000504	CcSEcCtD
Roflumilast—Decreased appetite—Docetaxel—prostate cancer	0.000108	0.0005	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000107	0.000497	CcSEcCtD
Roflumilast—Asthenia—Etoposide—prostate cancer	0.000107	0.000497	CcSEcCtD
Roflumilast—Connective tissue disorder—Doxorubicin—prostate cancer	0.000107	0.000497	CcSEcCtD
Roflumilast—Fatigue—Docetaxel—prostate cancer	0.000107	0.000496	CcSEcCtD
Roflumilast—Nausea—Mitoxantrone—prostate cancer	0.000106	0.000495	CcSEcCtD
Roflumilast—Immune system disorder—Epirubicin—prostate cancer	0.000106	0.000494	CcSEcCtD
Roflumilast—Infection—Prednisone—prostate cancer	0.000106	0.000493	CcSEcCtD
Roflumilast—Mediastinal disorder—Epirubicin—prostate cancer	0.000106	0.000493	CcSEcCtD
Roflumilast—Constipation—Docetaxel—prostate cancer	0.000106	0.000492	CcSEcCtD
Roflumilast—Dyspepsia—Capecitabine—prostate cancer	0.000106	0.000491	CcSEcCtD
Roflumilast—Nervous system disorder—Prednisone—prostate cancer	0.000105	0.000487	CcSEcCtD
Roflumilast—Decreased appetite—Capecitabine—prostate cancer	0.000104	0.000484	CcSEcCtD
Roflumilast—Skin disorder—Prednisone—prostate cancer	0.000104	0.000482	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000104	0.000481	CcSEcCtD
Roflumilast—Fatigue—Capecitabine—prostate cancer	0.000103	0.000481	CcSEcCtD
Roflumilast—Mental disorder—Epirubicin—prostate cancer	0.000103	0.000479	CcSEcCtD
Roflumilast—Constipation—Capecitabine—prostate cancer	0.000103	0.000477	CcSEcCtD
Roflumilast—Malnutrition—Epirubicin—prostate cancer	0.000102	0.000476	CcSEcCtD
Roflumilast—Feeling abnormal—Docetaxel—prostate cancer	0.000102	0.000474	CcSEcCtD
Roflumilast—Diarrhoea—Etoposide—prostate cancer	0.000102	0.000474	CcSEcCtD
Roflumilast—Gastrointestinal pain—Docetaxel—prostate cancer	0.000101	0.000471	CcSEcCtD
Roflumilast—Cardiac disorder—Doxorubicin—prostate cancer	0.000101	0.000469	CcSEcCtD
Roflumilast—Tension—Epirubicin—prostate cancer	0.0001	0.000467	CcSEcCtD
Roflumilast—Dysgeusia—Epirubicin—prostate cancer	0.0001	0.000466	CcSEcCtD
Roflumilast—Nervousness—Epirubicin—prostate cancer	9.94e-05	0.000462	CcSEcCtD
Roflumilast—Back pain—Epirubicin—prostate cancer	9.9e-05	0.00046	CcSEcCtD
Roflumilast—Feeling abnormal—Capecitabine—prostate cancer	9.88e-05	0.000459	CcSEcCtD
Roflumilast—Dizziness—Etoposide—prostate cancer	9.86e-05	0.000458	CcSEcCtD
Roflumilast—Muscle spasms—Epirubicin—prostate cancer	9.84e-05	0.000457	CcSEcCtD
Roflumilast—Immune system disorder—Doxorubicin—prostate cancer	9.83e-05	0.000457	CcSEcCtD
Roflumilast—Gastrointestinal pain—Capecitabine—prostate cancer	9.81e-05	0.000456	CcSEcCtD
Roflumilast—Mediastinal disorder—Doxorubicin—prostate cancer	9.81e-05	0.000456	CcSEcCtD
Roflumilast—Abdominal pain—Docetaxel—prostate cancer	9.79e-05	0.000455	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Prednisone—prostate cancer	9.73e-05	0.000452	CcSEcCtD
Roflumilast—Insomnia—Prednisone—prostate cancer	9.66e-05	0.000449	CcSEcCtD
Roflumilast—Mental disorder—Doxorubicin—prostate cancer	9.53e-05	0.000443	CcSEcCtD
Roflumilast—Urticaria—Capecitabine—prostate cancer	9.53e-05	0.000443	CcSEcCtD
Roflumilast—Ill-defined disorder—Epirubicin—prostate cancer	9.5e-05	0.000441	CcSEcCtD
Roflumilast—Abdominal pain—Capecitabine—prostate cancer	9.48e-05	0.000441	CcSEcCtD
Roflumilast—Vomiting—Etoposide—prostate cancer	9.48e-05	0.00044	CcSEcCtD
Roflumilast—Malnutrition—Doxorubicin—prostate cancer	9.47e-05	0.00044	CcSEcCtD
Roflumilast—Dyspepsia—Prednisone—prostate cancer	9.4e-05	0.000437	CcSEcCtD
Roflumilast—Rash—Etoposide—prostate cancer	9.4e-05	0.000437	CcSEcCtD
Roflumilast—Dermatitis—Etoposide—prostate cancer	9.39e-05	0.000436	CcSEcCtD
Roflumilast—Headache—Etoposide—prostate cancer	9.34e-05	0.000434	CcSEcCtD
Roflumilast—Tension—Doxorubicin—prostate cancer	9.3e-05	0.000432	CcSEcCtD
Roflumilast—Decreased appetite—Prednisone—prostate cancer	9.29e-05	0.000432	CcSEcCtD
Roflumilast—Dysgeusia—Doxorubicin—prostate cancer	9.28e-05	0.000431	CcSEcCtD
Roflumilast—Malaise—Epirubicin—prostate cancer	9.23e-05	0.000429	CcSEcCtD
Roflumilast—Fatigue—Prednisone—prostate cancer	9.21e-05	0.000428	CcSEcCtD
Roflumilast—Nervousness—Doxorubicin—prostate cancer	9.2e-05	0.000428	CcSEcCtD
Roflumilast—Vertigo—Epirubicin—prostate cancer	9.2e-05	0.000427	CcSEcCtD
Roflumilast—Back pain—Doxorubicin—prostate cancer	9.16e-05	0.000426	CcSEcCtD
Roflumilast—Constipation—Prednisone—prostate cancer	9.14e-05	0.000425	CcSEcCtD
Roflumilast—Hypersensitivity—Docetaxel—prostate cancer	9.13e-05	0.000424	CcSEcCtD
Roflumilast—Muscle spasms—Doxorubicin—prostate cancer	9.11e-05	0.000423	CcSEcCtD
Roflumilast—Palpitations—Epirubicin—prostate cancer	9.05e-05	0.00042	CcSEcCtD
Roflumilast—Asthenia—Docetaxel—prostate cancer	8.89e-05	0.000413	CcSEcCtD
Roflumilast—Nausea—Etoposide—prostate cancer	8.85e-05	0.000411	CcSEcCtD
Roflumilast—Hypersensitivity—Capecitabine—prostate cancer	8.84e-05	0.000411	CcSEcCtD
Roflumilast—Feeling abnormal—Prednisone—prostate cancer	8.8e-05	0.000409	CcSEcCtD
Roflumilast—Ill-defined disorder—Doxorubicin—prostate cancer	8.79e-05	0.000408	CcSEcCtD
Roflumilast—Gastrointestinal pain—Prednisone—prostate cancer	8.74e-05	0.000406	CcSEcCtD
Roflumilast—Myalgia—Epirubicin—prostate cancer	8.72e-05	0.000405	CcSEcCtD
Roflumilast—Anxiety—Epirubicin—prostate cancer	8.69e-05	0.000404	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	8.66e-05	0.000402	CcSEcCtD
Roflumilast—Discomfort—Epirubicin—prostate cancer	8.61e-05	0.0004	CcSEcCtD
Roflumilast—Asthenia—Capecitabine—prostate cancer	8.61e-05	0.0004	CcSEcCtD
Roflumilast—Malaise—Doxorubicin—prostate cancer	8.54e-05	0.000397	CcSEcCtD
Roflumilast—Vertigo—Doxorubicin—prostate cancer	8.51e-05	0.000395	CcSEcCtD
Roflumilast—Urticaria—Prednisone—prostate cancer	8.49e-05	0.000394	CcSEcCtD
Roflumilast—Diarrhoea—Docetaxel—prostate cancer	8.48e-05	0.000394	CcSEcCtD
Roflumilast—Abdominal pain—Prednisone—prostate cancer	8.45e-05	0.000392	CcSEcCtD
Roflumilast—Palpitations—Doxorubicin—prostate cancer	8.37e-05	0.000389	CcSEcCtD
Roflumilast—Infection—Epirubicin—prostate cancer	8.3e-05	0.000386	CcSEcCtD
Roflumilast—Diarrhoea—Capecitabine—prostate cancer	8.21e-05	0.000381	CcSEcCtD
Roflumilast—Nervous system disorder—Epirubicin—prostate cancer	8.19e-05	0.000381	CcSEcCtD
Roflumilast—Dizziness—Docetaxel—prostate cancer	8.19e-05	0.000381	CcSEcCtD
Roflumilast—Skin disorder—Epirubicin—prostate cancer	8.12e-05	0.000377	CcSEcCtD
Roflumilast—Myalgia—Doxorubicin—prostate cancer	8.07e-05	0.000375	CcSEcCtD
Roflumilast—Anxiety—Doxorubicin—prostate cancer	8.04e-05	0.000373	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	8.01e-05	0.000372	CcSEcCtD
Roflumilast—Discomfort—Doxorubicin—prostate cancer	7.97e-05	0.00037	CcSEcCtD
Roflumilast—Dizziness—Capecitabine—prostate cancer	7.93e-05	0.000369	CcSEcCtD
Roflumilast—Vomiting—Docetaxel—prostate cancer	7.88e-05	0.000366	CcSEcCtD
Roflumilast—Hypersensitivity—Prednisone—prostate cancer	7.87e-05	0.000366	CcSEcCtD
Roflumilast—Rash—Docetaxel—prostate cancer	7.81e-05	0.000363	CcSEcCtD
Roflumilast—Dermatitis—Docetaxel—prostate cancer	7.8e-05	0.000363	CcSEcCtD
Roflumilast—Headache—Docetaxel—prostate cancer	7.76e-05	0.000361	CcSEcCtD
Roflumilast—Infection—Doxorubicin—prostate cancer	7.68e-05	0.000357	CcSEcCtD
Roflumilast—Asthenia—Prednisone—prostate cancer	7.67e-05	0.000356	CcSEcCtD
Roflumilast—Vomiting—Capecitabine—prostate cancer	7.63e-05	0.000354	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Epirubicin—prostate cancer	7.61e-05	0.000354	CcSEcCtD
Roflumilast—Nervous system disorder—Doxorubicin—prostate cancer	7.58e-05	0.000352	CcSEcCtD
Roflumilast—Rash—Capecitabine—prostate cancer	7.56e-05	0.000351	CcSEcCtD
Roflumilast—Insomnia—Epirubicin—prostate cancer	7.56e-05	0.000351	CcSEcCtD
Roflumilast—Dermatitis—Capecitabine—prostate cancer	7.56e-05	0.000351	CcSEcCtD
Roflumilast—Headache—Capecitabine—prostate cancer	7.51e-05	0.000349	CcSEcCtD
Roflumilast—Skin disorder—Doxorubicin—prostate cancer	7.51e-05	0.000349	CcSEcCtD
Roflumilast—Nausea—Docetaxel—prostate cancer	7.36e-05	0.000342	CcSEcCtD
Roflumilast—Dyspepsia—Epirubicin—prostate cancer	7.36e-05	0.000342	CcSEcCtD
Roflumilast—Diarrhoea—Prednisone—prostate cancer	7.31e-05	0.00034	CcSEcCtD
Roflumilast—Decreased appetite—Epirubicin—prostate cancer	7.26e-05	0.000338	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Epirubicin—prostate cancer	7.21e-05	0.000335	CcSEcCtD
Roflumilast—Fatigue—Epirubicin—prostate cancer	7.2e-05	0.000335	CcSEcCtD
Roflumilast—Constipation—Epirubicin—prostate cancer	7.15e-05	0.000332	CcSEcCtD
Roflumilast—Nausea—Capecitabine—prostate cancer	7.12e-05	0.000331	CcSEcCtD
Roflumilast—Dizziness—Prednisone—prostate cancer	7.06e-05	0.000328	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Doxorubicin—prostate cancer	7.04e-05	0.000327	CcSEcCtD
Roflumilast—Insomnia—Doxorubicin—prostate cancer	6.99e-05	0.000325	CcSEcCtD
Roflumilast—Feeling abnormal—Epirubicin—prostate cancer	6.89e-05	0.00032	CcSEcCtD
Roflumilast—Gastrointestinal pain—Epirubicin—prostate cancer	6.83e-05	0.000318	CcSEcCtD
Roflumilast—Dyspepsia—Doxorubicin—prostate cancer	6.81e-05	0.000316	CcSEcCtD
Roflumilast—Vomiting—Prednisone—prostate cancer	6.79e-05	0.000316	CcSEcCtD
Roflumilast—Rash—Prednisone—prostate cancer	6.74e-05	0.000313	CcSEcCtD
Roflumilast—Dermatitis—Prednisone—prostate cancer	6.73e-05	0.000313	CcSEcCtD
Roflumilast—Decreased appetite—Doxorubicin—prostate cancer	6.72e-05	0.000312	CcSEcCtD
Roflumilast—Headache—Prednisone—prostate cancer	6.69e-05	0.000311	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Doxorubicin—prostate cancer	6.67e-05	0.00031	CcSEcCtD
Roflumilast—Fatigue—Doxorubicin—prostate cancer	6.67e-05	0.00031	CcSEcCtD
Roflumilast—Urticaria—Epirubicin—prostate cancer	6.64e-05	0.000308	CcSEcCtD
Roflumilast—Constipation—Doxorubicin—prostate cancer	6.61e-05	0.000307	CcSEcCtD
Roflumilast—Abdominal pain—Epirubicin—prostate cancer	6.61e-05	0.000307	CcSEcCtD
Roflumilast—Feeling abnormal—Doxorubicin—prostate cancer	6.37e-05	0.000296	CcSEcCtD
Roflumilast—Nausea—Prednisone—prostate cancer	6.35e-05	0.000295	CcSEcCtD
Roflumilast—Gastrointestinal pain—Doxorubicin—prostate cancer	6.32e-05	0.000294	CcSEcCtD
Roflumilast—Hypersensitivity—Epirubicin—prostate cancer	6.16e-05	0.000286	CcSEcCtD
Roflumilast—Urticaria—Doxorubicin—prostate cancer	6.14e-05	0.000285	CcSEcCtD
Roflumilast—Abdominal pain—Doxorubicin—prostate cancer	6.11e-05	0.000284	CcSEcCtD
Roflumilast—Asthenia—Epirubicin—prostate cancer	6e-05	0.000279	CcSEcCtD
Roflumilast—Diarrhoea—Epirubicin—prostate cancer	5.72e-05	0.000266	CcSEcCtD
Roflumilast—Hypersensitivity—Doxorubicin—prostate cancer	5.7e-05	0.000265	CcSEcCtD
Roflumilast—Asthenia—Doxorubicin—prostate cancer	5.55e-05	0.000258	CcSEcCtD
Roflumilast—Dizziness—Epirubicin—prostate cancer	5.53e-05	0.000257	CcSEcCtD
Roflumilast—Vomiting—Epirubicin—prostate cancer	5.31e-05	0.000247	CcSEcCtD
Roflumilast—Diarrhoea—Doxorubicin—prostate cancer	5.29e-05	0.000246	CcSEcCtD
Roflumilast—Rash—Epirubicin—prostate cancer	5.27e-05	0.000245	CcSEcCtD
Roflumilast—Dermatitis—Epirubicin—prostate cancer	5.26e-05	0.000245	CcSEcCtD
Roflumilast—Headache—Epirubicin—prostate cancer	5.23e-05	0.000243	CcSEcCtD
Roflumilast—Dizziness—Doxorubicin—prostate cancer	5.11e-05	0.000238	CcSEcCtD
Roflumilast—Nausea—Epirubicin—prostate cancer	4.96e-05	0.000231	CcSEcCtD
Roflumilast—Vomiting—Doxorubicin—prostate cancer	4.92e-05	0.000228	CcSEcCtD
Roflumilast—Rash—Doxorubicin—prostate cancer	4.87e-05	0.000227	CcSEcCtD
Roflumilast—Dermatitis—Doxorubicin—prostate cancer	4.87e-05	0.000226	CcSEcCtD
Roflumilast—Headache—Doxorubicin—prostate cancer	4.84e-05	0.000225	CcSEcCtD
Roflumilast—Nausea—Doxorubicin—prostate cancer	4.59e-05	0.000213	CcSEcCtD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CB—prostate cancer	2.37e-05	0.000252	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGF10—prostate cancer	2.36e-05	0.000252	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ADRB2—prostate cancer	2.34e-05	0.000249	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—JAK2—prostate cancer	2.3e-05	0.000246	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LPL—prostate cancer	2.3e-05	0.000245	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—MAP2K1—prostate cancer	2.3e-05	0.000245	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF1R—prostate cancer	2.28e-05	0.000243	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—IL2—prostate cancer	2.28e-05	0.000243	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CD—prostate cancer	2.28e-05	0.000243	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PDGFRB—prostate cancer	2.28e-05	0.000243	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—VAV3—prostate cancer	2.28e-05	0.000243	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CXCL8—prostate cancer	2.27e-05	0.000242	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HIF1A—prostate cancer	2.27e-05	0.000242	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—JAK2—prostate cancer	2.26e-05	0.000241	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CB—prostate cancer	2.26e-05	0.00024	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFBR2—prostate cancer	2.25e-05	0.000239	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ITGB3—prostate cancer	2.22e-05	0.000237	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—LEP—prostate cancer	2.21e-05	0.000236	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ITPR1—prostate cancer	2.21e-05	0.000235	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CAV1—prostate cancer	2.19e-05	0.000234	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LPL—prostate cancer	2.19e-05	0.000233	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CB—prostate cancer	2.19e-05	0.000233	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—IL2—prostate cancer	2.17e-05	0.000231	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PDGFRB—prostate cancer	2.17e-05	0.000231	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KDR—prostate cancer	2.17e-05	0.000231	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CXCL8—prostate cancer	2.17e-05	0.000231	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ERBB3—prostate cancer	2.15e-05	0.00023	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FGFR2—prostate cancer	2.15e-05	0.000229	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CB—prostate cancer	2.15e-05	0.000229	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ITGB3—prostate cancer	2.11e-05	0.000225	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ESR1—prostate cancer	2.11e-05	0.000225	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF1R—prostate cancer	2.11e-05	0.000225	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CXCL8—prostate cancer	2.1e-05	0.000224	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—JAK2—prostate cancer	2.09e-05	0.000223	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL2—prostate cancer	2.07e-05	0.000221	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TERT—prostate cancer	2.07e-05	0.00022	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CXCL8—prostate cancer	2.06e-05	0.00022	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—BAD—prostate cancer	2.06e-05	0.00022	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ERBB3—prostate cancer	2.05e-05	0.000218	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FGFR2—prostate cancer	2.05e-05	0.000218	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LPL—prostate cancer	2.03e-05	0.000216	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—IL2—prostate cancer	2.01e-05	0.000214	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PDGFRB—prostate cancer	2.01e-05	0.000214	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CG—prostate cancer	2e-05	0.000213	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APC—prostate cancer	2e-05	0.000213	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CB—prostate cancer	1.99e-05	0.000212	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EGF—prostate cancer	1.98e-05	0.00021	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IRS1—prostate cancer	1.98e-05	0.00021	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HIF1A—prostate cancer	1.98e-05	0.00021	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL2—prostate cancer	1.97e-05	0.00021	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TERT—prostate cancer	1.97e-05	0.000209	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ITGB3—prostate cancer	1.96e-05	0.000208	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LEP—prostate cancer	1.93e-05	0.000205	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—GSK3B—prostate cancer	1.92e-05	0.000204	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CAV1—prostate cancer	1.91e-05	0.000203	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CXCL8—prostate cancer	1.91e-05	0.000203	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ERBB3—prostate cancer	1.9e-05	0.000202	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGFR2—prostate cancer	1.89e-05	0.000202	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—INS—prostate cancer	1.89e-05	0.000202	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KDR—prostate cancer	1.89e-05	0.000201	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HIF1A—prostate cancer	1.88e-05	0.0002	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CREBBP—prostate cancer	1.85e-05	0.000197	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ESR1—prostate cancer	1.84e-05	0.000196	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LEP—prostate cancer	1.84e-05	0.000195	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IGF1—prostate cancer	1.83e-05	0.000195	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL2—prostate cancer	1.83e-05	0.000194	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—EGFR—prostate cancer	1.82e-05	0.000194	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TERT—prostate cancer	1.82e-05	0.000194	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CAV1—prostate cancer	1.82e-05	0.000194	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KDR—prostate cancer	1.8e-05	0.000192	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—BAD—prostate cancer	1.8e-05	0.000191	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAP2K1—prostate cancer	1.77e-05	0.000188	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CD—prostate cancer	1.76e-05	0.000187	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ESR1—prostate cancer	1.75e-05	0.000187	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3CA—prostate cancer	1.74e-05	0.000185	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APC—prostate cancer	1.74e-05	0.000185	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CG—prostate cancer	1.74e-05	0.000185	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HIF1A—prostate cancer	1.74e-05	0.000185	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SERPINE1—prostate cancer	1.74e-05	0.000185	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—KRAS—prostate cancer	1.72e-05	0.000183	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EGF—prostate cancer	1.72e-05	0.000183	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IRS1—prostate cancer	1.72e-05	0.000183	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—BAD—prostate cancer	1.71e-05	0.000182	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LEP—prostate cancer	1.7e-05	0.000181	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—FGF2—prostate cancer	1.68e-05	0.000179	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CAV1—prostate cancer	1.68e-05	0.000179	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GSK3B—prostate cancer	1.67e-05	0.000178	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KDR—prostate cancer	1.66e-05	0.000177	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOS3—prostate cancer	1.66e-05	0.000177	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CG—prostate cancer	1.66e-05	0.000176	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APC—prostate cancer	1.66e-05	0.000176	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—INS—prostate cancer	1.65e-05	0.000175	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EGF—prostate cancer	1.64e-05	0.000174	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IRS1—prostate cancer	1.64e-05	0.000174	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ESR1—prostate cancer	1.62e-05	0.000173	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CREBBP—prostate cancer	1.61e-05	0.000172	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—JAK2—prostate cancer	1.61e-05	0.000172	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IGF1—prostate cancer	1.59e-05	0.00017	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GSK3B—prostate cancer	1.59e-05	0.000169	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—EGFR—prostate cancer	1.59e-05	0.000169	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—BAD—prostate cancer	1.58e-05	0.000169	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3CA—prostate cancer	1.58e-05	0.000168	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MDM2—prostate cancer	1.57e-05	0.000168	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—INS—prostate cancer	1.57e-05	0.000167	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ERBB2—prostate cancer	1.55e-05	0.000165	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAP2K1—prostate cancer	1.54e-05	0.000164	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CREBBP—prostate cancer	1.54e-05	0.000164	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APC—prostate cancer	1.53e-05	0.000163	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CG—prostate cancer	1.53e-05	0.000163	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CB—prostate cancer	1.53e-05	0.000163	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CD—prostate cancer	1.53e-05	0.000163	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF1—prostate cancer	1.52e-05	0.000162	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3CA—prostate cancer	1.52e-05	0.000161	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IRS1—prostate cancer	1.51e-05	0.000161	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EGF—prostate cancer	1.51e-05	0.000161	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SERPINE1—prostate cancer	1.51e-05	0.000161	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—EGFR—prostate cancer	1.51e-05	0.000161	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—KRAS—prostate cancer	1.5e-05	0.00016	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CXCL8—prostate cancer	1.47e-05	0.000157	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GSK3B—prostate cancer	1.47e-05	0.000157	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAP2K1—prostate cancer	1.47e-05	0.000156	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FGF2—prostate cancer	1.46e-05	0.000156	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CD—prostate cancer	1.46e-05	0.000155	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—INS—prostate cancer	1.45e-05	0.000155	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOS3—prostate cancer	1.44e-05	0.000154	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CA—prostate cancer	1.44e-05	0.000154	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SERPINE1—prostate cancer	1.44e-05	0.000153	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN1B—prostate cancer	1.44e-05	0.000153	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—KRAS—prostate cancer	1.43e-05	0.000152	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—AKT1—prostate cancer	1.42e-05	0.000151	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CREBBP—prostate cancer	1.42e-05	0.000151	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CASP3—prostate cancer	1.41e-05	0.00015	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL2—prostate cancer	1.41e-05	0.00015	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—JAK2—prostate cancer	1.4e-05	0.00015	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF1—prostate cancer	1.4e-05	0.000149	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6—prostate cancer	1.4e-05	0.000149	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—EGFR—prostate cancer	1.4e-05	0.000149	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FGF2—prostate cancer	1.39e-05	0.000149	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CA—prostate cancer	1.38e-05	0.000147	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOS3—prostate cancer	1.37e-05	0.000146	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCND1—prostate cancer	1.37e-05	0.000146	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MDM2—prostate cancer	1.37e-05	0.000146	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CTNNB1—prostate cancer	1.36e-05	0.000145	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAP2K1—prostate cancer	1.36e-05	0.000144	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ERBB2—prostate cancer	1.35e-05	0.000144	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CD—prostate cancer	1.35e-05	0.000144	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—JAK2—prostate cancer	1.34e-05	0.000142	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CA—prostate cancer	1.33e-05	0.000142	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CB—prostate cancer	1.33e-05	0.000142	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SERPINE1—prostate cancer	1.33e-05	0.000142	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MMP9—prostate cancer	1.33e-05	0.000142	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN1A—prostate cancer	1.33e-05	0.000141	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PTEN—prostate cancer	1.32e-05	0.000141	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—KRAS—prostate cancer	1.32e-05	0.000141	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CA—prostate cancer	1.31e-05	0.00014	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MDM2—prostate cancer	1.3e-05	0.000139	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—AKT1—prostate cancer	1.29e-05	0.000138	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGF2—prostate cancer	1.29e-05	0.000137	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ERBB2—prostate cancer	1.29e-05	0.000137	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CXCL8—prostate cancer	1.28e-05	0.000136	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOS3—prostate cancer	1.27e-05	0.000136	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CB—prostate cancer	1.27e-05	0.000135	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EP300—prostate cancer	1.26e-05	0.000134	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN1B—prostate cancer	1.25e-05	0.000133	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—AKT1—prostate cancer	1.24e-05	0.000132	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—JAK2—prostate cancer	1.24e-05	0.000132	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SRC—prostate cancer	1.23e-05	0.000131	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CASP3—prostate cancer	1.23e-05	0.000131	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL2—prostate cancer	1.22e-05	0.00013	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CXCL8—prostate cancer	1.22e-05	0.00013	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6—prostate cancer	1.22e-05	0.00013	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CA—prostate cancer	1.21e-05	0.000129	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MDM2—prostate cancer	1.21e-05	0.000129	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—VEGFA—prostate cancer	1.2e-05	0.000127	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCND1—prostate cancer	1.19e-05	0.000127	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN1B—prostate cancer	1.19e-05	0.000127	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ERBB2—prostate cancer	1.19e-05	0.000127	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—STAT3—prostate cancer	1.18e-05	0.000126	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CTNNB1—prostate cancer	1.18e-05	0.000126	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—AKT1—prostate cancer	1.18e-05	0.000126	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CB—prostate cancer	1.17e-05	0.000125	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CASP3—prostate cancer	1.17e-05	0.000124	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL2—prostate cancer	1.17e-05	0.000124	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6—prostate cancer	1.16e-05	0.000124	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MMP9—prostate cancer	1.16e-05	0.000123	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN1A—prostate cancer	1.15e-05	0.000123	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PTEN—prostate cancer	1.15e-05	0.000123	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCND1—prostate cancer	1.14e-05	0.000121	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CXCL8—prostate cancer	1.13e-05	0.00012	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CTNNB1—prostate cancer	1.13e-05	0.00012	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—AKT1—prostate cancer	1.12e-05	0.00012	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MMP9—prostate cancer	1.1e-05	0.000118	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN1B—prostate cancer	1.1e-05	0.000117	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MYC—prostate cancer	1.1e-05	0.000117	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN1A—prostate cancer	1.1e-05	0.000117	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EP300—prostate cancer	1.1e-05	0.000117	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TGFB1—prostate cancer	1.1e-05	0.000117	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTEN—prostate cancer	1.1e-05	0.000117	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—AKT1—prostate cancer	1.09e-05	0.000116	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CASP3—prostate cancer	1.08e-05	0.000115	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL2—prostate cancer	1.08e-05	0.000115	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EGFR—prostate cancer	1.08e-05	0.000115	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6—prostate cancer	1.07e-05	0.000114	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AKT1—prostate cancer	1.07e-05	0.000114	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SRC—prostate cancer	1.07e-05	0.000114	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCND1—prostate cancer	1.05e-05	0.000112	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EP300—prostate cancer	1.05e-05	0.000111	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CTNNB1—prostate cancer	1.04e-05	0.000111	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—VEGFA—prostate cancer	1.04e-05	0.000111	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—STAT3—prostate cancer	1.03e-05	0.00011	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MMP9—prostate cancer	1.02e-05	0.000109	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SRC—prostate cancer	1.02e-05	0.000108	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN1A—prostate cancer	1.02e-05	0.000108	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KRAS—prostate cancer	1.02e-05	0.000108	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTEN—prostate cancer	1.01e-05	0.000108	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—VEGFA—prostate cancer	9.91e-06	0.000106	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AKT1—prostate cancer	9.9e-06	0.000105	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—STAT3—prostate cancer	9.81e-06	0.000104	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EP300—prostate cancer	9.68e-06	0.000103	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MYC—prostate cancer	9.57e-06	0.000102	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TGFB1—prostate cancer	9.55e-06	0.000102	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SRC—prostate cancer	9.41e-06	0.0001	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EGFR—prostate cancer	9.36e-06	9.98e-05	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CA—prostate cancer	9.34e-06	9.95e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—VEGFA—prostate cancer	9.16e-06	9.76e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MYC—prostate cancer	9.11e-06	9.71e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TGFB1—prostate cancer	9.09e-06	9.68e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—STAT3—prostate cancer	9.07e-06	9.67e-05	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TP53—prostate cancer	9.03e-06	9.62e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EGFR—prostate cancer	8.91e-06	9.5e-05	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KRAS—prostate cancer	8.85e-06	9.42e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MYC—prostate cancer	8.43e-06	8.98e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KRAS—prostate cancer	8.42e-06	8.97e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFB1—prostate cancer	8.41e-06	8.96e-05	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6—prostate cancer	8.27e-06	8.81e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EGFR—prostate cancer	8.25e-06	8.79e-05	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CA—prostate cancer	8.13e-06	8.66e-05	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TP53—prostate cancer	7.86e-06	8.38e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KRAS—prostate cancer	7.79e-06	8.3e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CA—prostate cancer	7.74e-06	8.24e-05	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AKT1—prostate cancer	7.63e-06	8.12e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TP53—prostate cancer	7.48e-06	7.97e-05	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6—prostate cancer	7.2e-06	7.67e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CA—prostate cancer	7.16e-06	7.63e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TP53—prostate cancer	6.92e-06	7.38e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6—prostate cancer	6.85e-06	7.3e-05	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AKT1—prostate cancer	6.64e-06	7.07e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6—prostate cancer	6.34e-06	6.75e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AKT1—prostate cancer	6.32e-06	6.73e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AKT1—prostate cancer	5.85e-06	6.23e-05	CbGpPWpGaD
